JACOBS LEVY EQUITY MANAGEMENT, INC
Position in PYXS — Pyxis Oncology, Inc.
CIK 884414
FLORHAM PARK, NJ
Position in PYXS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$673,055
+$539,116 QoQ
Shares Held
460,997
+664.1% QoQ
Ownership
0.728%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#11
of 78 holders
Holding Since
Sep 2024
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in PYXS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026JACOBS LEVY EQUITY MANAGEMENT, INC holds $705,368,973 across 85 Biotechnology names. PYXS ranks #58 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
214,160 | $165,468,582 | |
| 2 | INCY |
Incyte Corp
|
1,717,978 | $161,696,089 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
212,204 | $70,211,937 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
789,429 | $51,020,796 | |
| 5 | RARE |
Ultragenyx Pharmaceutical Inc.
|
1,431,071 | $29,980,937 | |
| 6 | EXEL |
Exelixis, Inc.
|
425,982 | $18,270,367 | |
| 7 | AUPH |
Aurinia Pharmaceuticals Inc.
|
1,097,189 | $16,260,340 | |
| 8 | ARVN |
Arvinas, Inc.
|
1,441,521 | $15,280,122 |
All Filings in PYXS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $673,055 | 460,997 | Shares | Sole | 2026-05-15 | |
| 2025-09-30 | $133,939 | 60,333 | Shares | Sole | 2025-11-17 | |
| 2024-12-31 | $939,026 | 601,940 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $1,405,022 | 382,840 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||